As on February 09, 2021, Cyclo Therapeutics Inc. (NASDAQ: CYTH) got off with the flyer as it spiked 18.81% to $13.33. During the day, the stock rose to $17.75 and sunk to $12.10 before settling in for the price of $11.22 at the close. Taking a more long-term approach, CYTH posted a 52-week range of $3.40-$30.00.
The company of the Healthcare sector’s yearbook sales growth during the past 5- year span was recorded -8.50%. Meanwhile, its Annual Earning per share during the time was -42.80%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -33.80%. This publicly-traded company’s shares outstanding now amounts to $151.95 million, simultaneously with a float of $4.05 million. The organization now has a market capitalization sitting at $77.18 million.
It is imperative to bring your focus towards the efficiency factor of the conglomerate that has a total of 8 employees. It has generated 125,900 per worker during the last fiscal year. Meanwhile, its income per employee was -941,567. The stock had 6.72 Receivables turnover and 0.28 Total Asset turnover. For the Profitability, stocks gross margin was -97.34, operating margin was -749.06 and Pretax Margin of -747.87.
Cyclo Therapeutics Inc. (CYTH) Ownership Facts and Figures
Another important factor to analyze is how key investors are playing towards the stock of the Biotechnology industry. Cyclo Therapeutics Inc.’s current insider ownership accounts for 8.60%, in contrast to 0.10% institutional ownership. According to the most recent insider trade that took place on Jan 26, this organization’s Director bought 2,201 shares at the rate of 6.60, making the entire transaction reach 14,527 in total value, affecting insider ownership by 57,614. Preceding that transaction, on Jan 25, Company’s Director bought 7,799 for 6.30, making the whole transaction’s value amount to 49,108. This particular insider is now the holder of 55,413 in total.
Cyclo Therapeutics Inc. (CYTH) Earnings and Revenue Records
If we go through the results of last quarter, which was made public on 12/30/2019, the company posted -$2 earnings per share (EPS) for the quarter, coming under the agreed prediction (set at -$1) by -$1. This company achieved a net margin of -747.87 while generating a return on equity of -731.82. Wall Street market experts anticipate that the next fiscal year will bring earnings of 0 per share during the current fiscal year.
Cyclo Therapeutics Inc.’s EPS decrease for this current 12-month fiscal period is -33.80% and is forecasted to reach -1.75 in the upcoming year.
Cyclo Therapeutics Inc. (NASDAQ: CYTH) Trading Performance Indicators
Let’s observe the current performance indicators for Cyclo Therapeutics Inc. (CYTH). It’s Quick Ratio in the last reported quarter now stands at 0.80. The Stock has managed to achieve an average true range (ATR) of 1.71. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 77.18.
In the same vein, CYTH’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -0.07, a figure that is expected to reach -0.33 in the next quarter, and analysts are predicting that it will be -1.75 at the market close of one year from today.
Technical Analysis of Cyclo Therapeutics Inc. (CYTH)
Through scrutinizing the latest numbers posted by the [Cyclo Therapeutics Inc., CYTH], it can be observed that its last 5-days Average volume of 4.23 million was better the volume of 1.79 million, it posted the year before. During the previous 9 days, stock’s Stochastic %D was recorded 55.56% While, its Average True Range was 2.21.